Author: Nishtha Mehrotra | EQMint
Synopsis:
- Sudarshan Pharma reported a 28.5% year-on-year rise in Q2 FY27 revenue to ₹216.97 crore.
- Consolidated profit attributable to owners increased 93.3% to ₹8.09 crore.
- The board approved a potential ₹1,500 crore fundraising plan and decided to discontinue manufacturing at its Palghar unit.
Sudarshan Pharma Industries Limited reported stronger financial performance for the second quarter of FY27, with growth in both revenue and profit.
The company recorded consolidated revenue from operations of ₹216.97 crore in Q2 FY27, compared with ₹168.87 crore in the corresponding quarter last year. Profit attributable to owners rose to ₹8.09 crore from ₹4.18 crore, marking a year-on-year increase of approximately 93%.
For the first half of FY27, revenue from operations stood at ₹391.39 crore, against ₹314.13 crore in H1 FY26. Profit attributable to owners increased to ₹13.94 crore from ₹8.22 crore.
Alongside the results, the board approved raising up to ₹1,500 crore through foreign currency convertible bonds and other securities, subject to applicable requirements. It also decided to discontinue manufacturing operations at the company’s Palghar unit as part of its operational and cost-rationalization measures.
The company also completed its migration from the BSE SME platform to the BSE Main Board on October 27, 2026.
Source: https://www.bseindia.com/xml-data/corpfiling/AttachLive/204529f0-ec1c-43a0-a246-6487b64b1a8e.pdf
Disclaimer: This article is for information purposes only and is not investment advice.
For more such information, visit EQMint
Join our WhatsApp channel for timely updates: Whatsapp.
